Bayer and Versant’s big bet on stem cells
Bayer and Versant Ventures, which invested $225m in Bluerock Therapeutics, a business that will focus on cardiovascular disease as its lead programme.
Read more from EP Vantage
Share:
Bayer and Versant Ventures, which invested $225m in Bluerock Therapeutics, a business that will focus on cardiovascular disease as its lead programme.